R
Robert Orenstein
Researcher at Mayo Clinic
Publications - 102
Citations - 3712
Robert Orenstein is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Clostridium difficile & Medicine. The author has an hindex of 22, co-authored 90 publications receiving 3077 citations. Previous affiliations of Robert Orenstein include Veterans Health Administration & University of Rochester.
Papers
More filters
Journal ArticleDOI
Risk factors for opportunistic infections in patients with inflammatory bowel disease.
Murat Törüner,Edward V. Loftus,W. Scott Harmsen,Alan R. Zinsmeister,Robert Orenstein,William J. Sandborn,Jean-Frederic Colombel,Laurence J. Egan,Laurence J. Egan +8 more
TL;DR: Immunosuppressive medications, especially when used in combination, and older age are associated with increased risk of opportunistic infections in inflammatory bowel disease patients.
Journal ArticleDOI
The epidemiology of community-acquired Clostridium difficile infection: a population-based study
Sahil Khanna,Darrell S. Pardi,Scott Aronson,Scott Aronson,Patricia P. Kammer,Robert Orenstein,Jennifer L. St. Sauver,W. Scott Harmsen,Alan R. Zinsmeister +8 more
TL;DR: In this population-based cohort, a significant proportion of cases of CDI occurred in the community, and patients were younger and had less severe infection than those with hospital-acquired infection.
Journal Article
Urinary tract infections in adults.
Robert Orenstein,Edward S. Wong +1 more
TL;DR: The most effective therapy for an uncomplicated infection is a three-day course of trimethoprim-sulfamethoxazole, and asymptomatic bacteriuria rarely requires treatment and is not associated with increased morbidity in elderly patients.
Journal ArticleDOI
Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
Robert Orenstein,Erik R. Dubberke,Robert Hardi,Arnab Ray,Kathleen M. Mullane,Darrell S. Pardi,Mayur Ramesh,Erik R. Dubberke,Ciaran Kelly,Paul Mariani,Misra Bg,Connie S. Price,Dimitri Drekonja +12 more
TL;DR: Administration of RBX2660 via enema appears to be safe and effective among patients with recurrent or severe CDI, and the frequency and severity of AEs decreased over time.
Journal ArticleDOI
Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility
TL;DR: It is reported that PPI usage at low and high dosages resulted in decreases to observed operational taxonomic unit (OTU) counts after both 1 week and 1 month, and the hypothesis that PPIs disrupt the healthy human gut microbiome is supported in this group.